AM-Pharma is a Dutch clinical stage biopharmaceutical company developing a treatment for acute kidney injury (AKI) that could be lifesaving. The Company does not produce face masks or other medical equipment.
The incidence of UC in the Western market is around 1.5 million patients, of which 60% have a moderate-to-severe form.
For patients failing first line treatment with 5-ASA there is a need for therapies that are safe, remain efficacious over time and are convenient to use.
As a potential biologic treatment, Alkaline Phosphatase (AP) would provide three key differentiating features: